Clinical Sequencing

Actionable and affordable testing

Hereditary Cancer Testing

Approximately 1 in 6 people in Southeast Asia will be affected by cancer during their lifetimes 1. Hereditary cancers make up 5-10% 2 of cancer cases and are caused by inherited pathogenic germline mutations in one or more genes.

Hereditary cancer testing is key to identifying patients and families who may be at increased risk of developing certain types of cancer for early detection and prevention 3,4.

Percentage of cancer patients with germline mutations 5

Recent research revealed that the high germline-positive rate (pathogenic germline variants) was detected as >30% in a large, diverse cancer patient population (n=2,023)5.

Indications for testing

Patients with more than 1 primary cancers

Patients with rare cancers at any age

3 or more close family members diagnosed with cancer

Age of cancers diagnosed for close family members is younger than 50

History of cancer which has a high incidence in the individuals ethnic group

Individuals with previous targeted genetic testing who may benefit from an extended panel

References
  1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
    CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
  2. ACOG Committee Opinion Number Number 793, 2019. Hereditary Cancer Syndromes and Risk Assessment.
  3. Lincoln SE, Nussbaum RL, Kurian AW, et al. Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer.
    JAMA Netw Open. 2020;3(10):e2019452.
  4. Pollard S, Kalloger S, Weymann D, et al. Genetic testing for hereditary cancer syndromes: patient recommendations for improved risk communication.
    Health Expect. 2020;23(4):884-892. doi:10.1111/hex.13062.
  5. Lincoln SE, Nussbaum RL, Kurian AW, et al. Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer
    [published correction appears in JAMA Netw Open.2021 Jul 1;4(7):e2123147].
    JAMA Netw Open. 2020;3(10):e2019452. Published 2020 Oct 1. doi:10.1001/jamanetworkopen.2020.19452

Whole Exome Sequencing

Through robust sequencing of up to 30,000 genes, Whole Exome Sequencing can provide important information about the underlying genetic causes to guide treatment decisions.

  • 150x average sequencing depth
  • 99.4% of reportable bases covered at >20x depth1,2.

WES Diagnosis Rate

29%

Proband WES

 

 

 

30%

WES Trio

 

 

 

39%

Critical WES Trio

 

 

 

41%

Prenatal WES Trio

Indications for testing

Exhausted Genetic testing options

Patients with a long list of differential diagnoses

Atypical presentation of disease

Whole Genome Sequencing

Whole Genome Sequencing (WGS) is an analysis of a patient’s entire nuclear and mitochondrial genomes. Compared to gene panels which only examine specific changes in a small subset of DNA, WGS can capture virtually all disease-causing genetic variations in both coding and non-coding regions, making it the most comprehensive germline genetic testing.

It is suitable for patients who have a broad spectrum of phenotypic features without an obvious clinical diagnosis.

Indications for testing

Intellectual disability

Autism spectrum disorders

Differential diagnosis

Development delays

Multiple congenital anomalies

Failure to thrive

Dysmorphic features

Epilepsy syndromes

Patients with extensive disease

Neurodevelopmental disorders

How to order

Complete the Test Requisition Form & Patient Consent Form

Collect and ship patient’s specimen

Receive report via email

Baylor Genetics’s preferred partner in Southeast Asia.

40 + Years
of Innovation

4 Million +
Clinical Test Performed

1 Million +
Families Helped

Baylor Genetics pioneered the history of genetic testing, is accredited by the College of American Pathologists (CAP) and certified under the Clinical Laboratory Improvement Amendments (CLIA).

Copyright © 2022 MiRXES Pte Ltd. All rights reserved. | Privacy Policy
Scroll to Top